文献速递治疗药物监测与药物基因组学药物不良反应与药物警戒

伏立康唑治疗侵袭性曲霉病优化:需评估药物基因组学与炎症状态

Optimization of voriconazole therapy for treatment of invasive aspergillosis: Pharmacogenomics and inflammatory status need to be evaluated.
PubMed 文献 · Br J Clin Pharmacol · 2020-12-13

本研究前瞻性观察血液病患者伏立康唑治疗,评估联合CYP2C19和CYP3A基因型的遗传评分预测初始谷浓度不足(<1 mg/L)的效用。43例患者中,遗传评分≥2对初始谷浓度不足的阳性预测值为0.31,且初始谷浓度与遗传评分无关。多变量分析显示CRP是剂量调整后伏立康唑谷浓度的独立决定因素(P < .0001)。

要点

  • 联合CYP2C19和CYP3A的遗传评分未能预测炎症患者的伏立康唑低暴露。
  • CRP是剂量调整后伏立康唑谷浓度的独立决定因素(P < .0001)。
  • 伏立康唑个体化给药策略除药物遗传变异外,应整合患者炎症状态。

核心结论

  • 联合遗传评分不能预测炎症患者的伏立康唑低暴露,伏立康唑剂量个体化应整合炎症状态与药物遗传变异。

研究设计与样本

  • 前瞻性观察研究,纳入43例接受伏立康唑治疗的血液病患者,其中41例为治愈性适应症。
  • 确定联合CYP2C19和CYP3A基因型的遗传评分,评分越高代谢越快。
  • 评估遗传评分对初始伏立康唑谷浓度及纵向治疗药物监测中全部159次谷浓度的影响。

主要发现

  • 遗传评分≥2对初始谷浓度不足的阳性预测值为0.31。
  • 初始伏立康唑谷浓度与遗传评分无关。
  • 患者CRP水平中位数(Q1-Q3)为43.0(11.0-110.0)mg/L。
  • 多变量分析显示CRP是剂量调整后伏立康唑谷浓度的独立决定因素(P < .0001)。

临床怎么用

  • 伏立康唑剂量个体化时应考虑患者炎症状态(如CRP水平),而不仅依赖药物遗传变异。

局限性

  • 遗传评分与谷浓度缺乏关联可能与患者炎症状态有关。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Cytochrome 2C19 genotype-directed dosing of voriconazole (VRC) reduces the incidence of insufficient VRC trough concentrations (Cmin ) but does not account for CYP3A polymorphisms, also involved in VRC metabolism. This prospective observational study aimed to evaluate the utility of a genetic score combining CYP2C19 and CYP3A genotypes to predict insufficient initial VRC Cmin (<1 mg/L). METHODS: The genetic score was determined in hematological patients treated with VRC. The higher the genetic score, the faster the metabolism of the patient. The impact of the genetic score was evaluated considering initial VRC Cmin and all VRC Cmin (n = 159) determined during longitudinal therapeutic drug monitoring. RESULTS: Forty-three patients were included, of whom 41 received VRC for curative indication. Thirty-six patients had a genetic score ≥2, of whom 11 had an initial insufficient VRC Cmin . A genetic score ≥2 had a positive predictive value of 0.31 for having an initial insufficient VRC Cmin and initial VRC Cmin was not associated with the genetic score. The lack of association between the genetic score and VRC Cmin may be related to the inflammatory status of the patients (C-reactive protein [CRP] levels: median [Q1-Q3]: 43.0 [11.0-110.0] mg/L), as multivariate analysis performed on all VRC Cmin identified CRP as an independent determinant of the VRC Cmin adjusted for dose (P < .0001). CONCLUSION: The combined genetic score did not predict low VRC exposure in patients with inflammation, which is frequent in patients with invasive fungal infections. Strategies for the individualization of VRC dose should integrate the inflammatory status of patients in addition to pharmacogenetic variants.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Gautier-Veyret E, Thiebaut-Bertrand A, Roustit M, et al. Optimization of voriconazole therapy for treatment of invasive aspergillosis: Pharmacogenomics and inflammatory status need to be evaluated. Br J Clin Pharmacol. 2020. PMID: 33217017. doi:10.1111/bcp.14661

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。